Wirth T - Search Results

1

Targeting of biotinylated compounds to its target tissue using a low-density lipoprotein receptor-avidin fusion protein.

Lehtolainen P, Wirth T, Taskinen AK, Lehenkari P, Leppänen O, Lappalainen M, Pulkkanen K, Marttila A, Marjomäki V, Airenne KJ, Horton M, Kulomaa MS, Ylä-Herttuala S. Lehtolainen P, et al. Among authors: wirth t. Gene Ther. 2003 Dec;10(25):2090-7. doi: 10.1038/sj.gt.3302120. Gene Ther. 2003. PMID: 14595382

2

Avidin fusion protein-expressing lentiviral vector for targeted drug delivery.

Lesch HP, Pikkarainen JT, Kaikkonen MU, Taavitsainen M, Samaranayake H, Lehtolainen-Dalkilic P, Vuorio T, Määttä AM, Wirth T, Airenne KJ, Ylä-Herttuala S. Lesch HP, et al. Among authors: wirth t. Hum Gene Ther. 2009 Aug;20(8):871-82. doi: 10.1089/hum.2009.007. Hum Gene Ther. 2009. PMID: 19419273

3

Efficient gene therapy based targeting system for the treatment of inoperable tumors.

Wirth T, Pikkarainen JT, Samaranayake HD, Lehtolainen-Dalkilic P, Lesch HP, Airenne KJ, Marjomäki V, Ylä-Herttuala SP. Wirth T, et al. J Gene Med. 2012 Apr;14(4):221-30. doi: 10.1002/jgm.2619. J Gene Med. 2012. PMID: 22411578

4

Truncated vesicular stomatitis virus G protein improves baculovirus transduction efficiency in vitro and in vivo.

Kaikkonen MU, Räty JK, Airenne KJ, Wirth T, Heikura T, Ylä-Herttuala S. Kaikkonen MU, et al. Among authors: wirth t. Gene Ther. 2006 Feb;13(4):304-12. doi: 10.1038/sj.gt.3302657. Gene Ther. 2006. PMID: 16267571

5

Magnetic resonance imaging of viral particle biodistribution in vivo.

Räty JK, Liimatainen T, Wirth T, Airenne KJ, Ihalainen TO, Huhtala T, Hamerlynck E, Vihinen-Ranta M, Närvänen A, Ylä-Herttuala S, Hakumäki JM. Räty JK, et al. Among authors: wirth t. Gene Ther. 2006 Oct;13(20):1440-6. doi: 10.1038/sj.gt.3302828. Epub 2006 Jul 20. Gene Ther. 2006. PMID: 16855615

6

Adenovirus mediated herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant glioma.

Määttä AM, Samaranayake H, Pikkarainen J, Wirth T, Ylä-Herttuala S. Määttä AM, et al. Among authors: wirth t. Curr Gene Ther. 2009 Oct;9(5):356-67. doi: 10.2174/156652309789753365. Curr Gene Ther. 2009. PMID: 19860650 Review.

7

History of gene therapy.

Wirth T, Parker N, Ylä-Herttuala S. Wirth T, et al. Gene. 2013 Aug 10;525(2):162-9. doi: 10.1016/j.gene.2013.03.137. Epub 2013 Apr 23. Gene. 2013. PMID: 23618815 Review.

8

Soluble vascular endothelial growth factor receptor-1 improves therapeutic efficacy of suicide gene therapy in an angiogenesis-independent manner.

Samaranayake HD, Pikkarainen JT, Wirth T, Stedt H, Lesch HP, Dragneva G, Vuorio T, Määttä AM, Airenne K, Ylä-Herttuala S. Samaranayake HD, et al. Among authors: wirth t. Hum Gene Ther. 2014 Nov;25(11):942-54. doi: 10.1089/hum.2013.191. Epub 2014 Sep 19. Hum Gene Ther. 2014. PMID: 25072110

9

Doxycycline-regulated lentiviral vector system with a novel reverse transactivator rtTA2S-M2 shows a tight control of gene expression in vitro and in vivo.

Koponen JK, Kankkonen H, Kannasto J, Wirth T, Hillen W, Bujard H, Ylä-Herttuala S. Koponen JK, et al. Among authors: wirth t. Gene Ther. 2003 Mar;10(6):459-66. doi: 10.1038/sj.gt.3301889. Gene Ther. 2003. PMID: 12621450

10

Gene technology based therapies in the brain.

Wirth T, Ylä-Herttuala S. Wirth T, et al. Adv Tech Stand Neurosurg. 2006;31:3-32. doi: 10.1007/3-211-32234-5_1. Adv Tech Stand Neurosurg. 2006. PMID: 16768302 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

697 results

Search Page

Filters